Continued Improvements in Motor Milestones in Infants with Type I Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi^™

PTC Therapeutics, Inc. announced that results from Part II of the pivotal FIREFISH trial demonstrated that infants with type 1 spinal muscular atrophy treated with Evrysdi^™ obtained increases in survival and sustained improvements in achieving key motor milestones, including head control, sitting, rolling over, and further developing towards acquiring the ability to stand, and walk.